Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

4 things on the horizon in childhood cancer

Lisa Diller, MD
Meds
September 21, 2015
Share
Tweet
Share

The 20th century saw striking advances in curing childhood cancer, primarily as a result of the discovery that broadly toxic chemotherapy agents could kill malignant cells. As a result, pediatric cancer, once a virtually incurable disease, now enjoys an overall long-term survival rate that tops 80 percent. In the 21st century, attention is turning to newer agents that promise to open additional, less toxic avenues to cure.  As we mark Childhood Cancer Awareness Month 2015 throughout September, here are four things on the horizon for pediatric cancer.

Precision medicine. Treatment for cancers is now being transformed because we can genetically characterize an individual’s tumor, finding genetic changes that suggest specific targeted therapies.  These therapies are developed for specific targets that may be implicated in a wide variety of pediatric and adult cancers.

A cancer’s biology, rather than its location in the body or the age of the patient, becomes the salient factor. Drugs that are proving effective at treating an adult lymphoma, for instance, can also treat a pediatric solid tumor with similar biologic characteristics. Likewise, a discovery in pediatric cancer can open new avenues of treatment for adult cancers. Still, there are barriers to overcome in bringing these discoveries to children with cancer. We need drugs in liquid form for young children, yet many drugs are being developed only as pills. We need preclinical testing in pediatric models and efficient early phase trials to establish the appropriate dosing for children. We must recognize that some pathways implicated in the development of a childhood cancer might be different from the pathways indicated in adult cancers, but there may still be crossover in terms of the therapeutic agents themselves. Pediatric cancers often involve changes in the epigenome — or in gene regulation — rather than mutations or abnormalities in gene sequencing. The question is can we use the same pathways being used in precision medicine to target epigenetic changes.

Immunotherapy. Immunotherapy is another new approach generating excitement in the treatment of pediatric and adult cancers. The Food and Drug Administration recently approved Unituxin™ (dinutuximab), an antibody agent for high-risk neuroblastoma, making it the first immunotherapy drug for pediatric cancer to earn FDA approval.

Meanwhile, promising pediatric trials are underway for an immunotherapy approach that genetically modifies a patient’s T-cells to recognize tumor cells in treatment-resistant leukemia. There is a lot of enthusiasm about similarly modifying the immune system’s T-cells to treat other cancers. Exciting advances are being made in adult oncology in immune checkpoint blockade therapy that uses drugs to teach a patient’s own immune system to recognize and reject tumor cells. Already there have been dramatic advances in melanoma outcomes and promising results in other adult-onset cancers. We are beginning to learn how to use this approach in pediatric cancers. There is also a lot of interest in looking at specific cancers whose genetic mutations may act as “neoantigens,” or new antigens, suggesting another potential avenue for immunotherapy.

Reducing toxicity. The improved cure rates that characterized the last half of the 20th century came at a cost, as chemotherapy and radiation often have long-term negative effects that appeared as more treated children survived into adulthood.

Many developed serious chronic conditions, including heart disease, infertility, and secondary malignancies. Since the late 20th century, we have increasingly sought ways to reduce the toxicity of treatment to maintain cure rates with fewer late effects. These efforts will continue.  Both targeted therapies and immunotherapy are promising not only because of their potential curative powers but also because they are potentially less toxic than standard chemotherapy. Clinicians also continue to explore ways to reduce radiation, as well as to make it more targeted to the tumor and involve less normal tissue.

We will likely have information, in the years to come, that will predict who is at higher risk for specific toxicities. This may help clinicians, parents and patients make decisions about best therapies, factoring in not only the likelihood of cure but also issues around long-term quality of life.

Global health. The strides in improved cure rates in North America and Europe have often not reached the developing world. Meanwhile, as improved health care systems reduce the risk of childhood death from malnutrition, diarrhea, and infectious diseases, resources in developing countries can be directed toward the care of children with cancer.

Today, clinicians in the United States, Canada, and Europe are working with clinicians in Latin America, Africa and parts of Asia to improve outcomes. Because pediatric cancers are rare, pediatric oncology is a global community accustomed to collaborating internationally, which offers a good platform for a stronger focus on improving survival of childhood cancer globally.   Understanding the patterns of cancer throughout the world and differences in incidence in different countries may bring insights into understanding the causes of childhood cancer, as well.

Lisa Diller is chief medical officer, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and director, David B. Perini Jr. Quality of Life Clinic.

Image credit: Shutterstock.com

Prev

Pain tolerance: A story of two patients

September 21, 2015 Kevin 14
…
Next

How good of a clinician are you?

September 21, 2015 Kevin 4
…

ADVERTISEMENT

Tagged as: Oncology/Hematology, Pediatrics

Post navigation

< Previous Post
Pain tolerance: A story of two patients
Next Post >
How good of a clinician are you?

ADVERTISEMENT

More by Lisa Diller, MD

  • a desk with keyboard and ipad with the kevinmd logo

    5 things OB/GYNs should know about treating survivors of childhood cancer

    Lisa Diller, MD
  • a desk with keyboard and ipad with the kevinmd logo

    5 things internists should know about treating survivors of childhood cancer

    Lisa Diller, MD

Related Posts

  • Cancer patients who want to take unproven supplements

    Marc Braunstein, MD, PhD
  • We have a shot at preventing cervical cancer

    Lisa N. Abaid, MD, MPH
  • Hormone replacement therapy is still linked to cancer

    Martha Rosenberg
  • Using the Avengers to explain how cancer treatments work

    Jennifer Lycette, MD
  • Obstruction of medical justice: How health care fails patients with cancer

    Miriam A. Knoll, MD
  • Despite progress in cancer care, cost and equity challenges still must be addressed

    David M. Aboulafia, MD

More in Meds

  • FDA delays could end vital treatment for rare disease patients

    GJ van Londen, MD
  • Pharmacists are key to expanding Medicaid access to digital therapeutics

    Amanda Matter
  • How medicine repurposing enables value-based pain management and insomnia therapy

    Olumuyiwa Bamgbade, MD
  • Forced voicemail and diagnosis codes are endangering patient access to medications

    Arthur Lazarus, MD, MBA
  • From stigma to science: Rethinking the U.S. drug scheduling system

    Artin Asadipooya
  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
  • Recent Posts

    • Why the heart of medicine is more than science

      Ryan Nadelson, MD | Physician
    • How Ukrainian doctors kept diabetes care alive during the war

      Dr. Daryna Bahriy | Physician
    • Why Grok 4 could be the next leap for HIPAA-compliant clinical AI

      Harvey Castro, MD, MBA | Tech
    • How women physicians can go from burnout to thriving

      Diane W. Shannon, MD, MPH | Physician
    • What a childhood stroke taught me about the future of neurosurgery and the promise of vagus nerve stimulation

      William J. Bannon IV | Conditions
    • Beyond burnout: Understanding the triangle of exhaustion [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
  • Recent Posts

    • Why the heart of medicine is more than science

      Ryan Nadelson, MD | Physician
    • How Ukrainian doctors kept diabetes care alive during the war

      Dr. Daryna Bahriy | Physician
    • Why Grok 4 could be the next leap for HIPAA-compliant clinical AI

      Harvey Castro, MD, MBA | Tech
    • How women physicians can go from burnout to thriving

      Diane W. Shannon, MD, MPH | Physician
    • What a childhood stroke taught me about the future of neurosurgery and the promise of vagus nerve stimulation

      William J. Bannon IV | Conditions
    • Beyond burnout: Understanding the triangle of exhaustion [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

4 things on the horizon in childhood cancer
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...